TARGETING NIK, A KEY REGULATOR OF THE NON-CANONICAL NF-ΚB PATHWAY, HOLDS IMMENSE THERAPEUTIC POTENTIAL IN CANCER AND AUTOIMMUNE DISEASES.

At Nikaia Pharmaceuticals, we are pioneering a groundbreaking approach to treating cancer and autoimmune diseases by blocking NIK (NF-κB-inducing kinase) selectively. Our precision therapeutics target the root causes of disease to create safer, more effective treatments.

UNLOCKING CANCER TREATMENT BREAKTHROUGHS

NIK overactivation plays a critical role in the progression of hard-to-treat cancers, such as melanoma, pancreas, and colon cancer.

When overactive, NIK is known to:

  • Fuel tumor growth and survival

  • Drive treatment resistance

  • Promote inflammation and blood vessel formation that supports metastasis

Our solution: Blocking NIK

We are developing cutting-edge small molecule therapies designed to:

  • Shrink tumors

  • Disrupt cancer's survival mechanisms

  • Enhance the effectiveness of existing treatments like chemotherapy and immunotherapy

Unlike other NIK-targeted approaches, which act on the kinase ligand-binding site, our small molecules function allosterically and block NIK activity. We believe this strategy will be safer and more effective.

REIMAGINING AUTOIMMUNE TREATMENT

In autoimmune disorders such as bullous pemphigoid, rheumatoid arthritis, lupus, and multiple sclerosis, NIK hyperactivates B cells.

This leads to:

  • Chronic inflammation

  • Progressive tissue damage

Our approach: recalibrate the immune system by blocking NIK selectively

Nikaia’s next-generation NIK blockers aim to:

  • Reduce inflammation

  • Restore immune balance without broad immunosuppression